



Clinical trial results:

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus Summary

| | |
|--------------------------|-------------------------|
| EudraCT number | 2017-005026-37 |
| Trial protocol | GB AT BE HU CZ GR NL HR |
| Global end of trial date | 09 March 2022 |

Results information

| | |
|--------------------------------|-----------------|
| Result version number | v1 |
| This version publication date | 27 October 2022 |
| First version publication date | 27 October 2022 |

Trial information

Trial identification

| | |
|-----------------------|-------------|
| Sponsor protocol code | I4V-MC-JAHZ |
|-----------------------|-------------|

Additional study identifiers

| | |
|------------------------------------|---------------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT03616912 |
| WHO universal trial number (UTN) | - |
| Other trial identifiers | Trial Number: 16676 |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Eli Lilly and Company |
| Sponsor organisation address | Lilly Corporate Center, Indianapolis, IN, United States, 46285 |
| Public contact | Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877CTLilly, |
| Scientific contact | Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 8772854559, |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|---------------|
| Analysis stage | Final |
| Date of interim/final analysis | 09 March 2022 |
| Is this the analysis of the primary completion data? | No |

| | |
|----------------------------------|---------------|
| Global end of trial reached? | Yes |
| Global end of trial date | 09 March 2022 |
| Was the trial ended prematurely? | Yes |

Notes:

General information about the trial

Main objective of the trial:

The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

| | |
|---|----------------|
| Actual start date of recruitment | 02 August 2018 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------------------|
| Country: Number of subjects enrolled | Australia: 31 |
| Country: Number of subjects enrolled | Austria: 3 |
| Country: Number of subjects enrolled | Belgium: 4 |
| Country: Number of subjects enrolled | Brazil: 83 |
| Country: Number of subjects enrolled | China: 116 |
| Country: Number of subjects enrolled | Croatia: 10 |
| Country: Number of subjects enrolled | Czechia: 38 |
| Country: Number of subjects enrolled | Germany: 45 |
| Country: Number of subjects enrolled | Greece: 18 |
| Country: Number of subjects enrolled | Hungary: 50 |
| Country: Number of subjects enrolled | Israel: 8 |
| Country: Number of subjects enrolled | Mexico: 136 |
| Country: Number of subjects enrolled | Netherlands: 2 |
| Country: Number of subjects enrolled | Russian Federation: 71 |
| Country: Number of subjects enrolled | Switzerland: 8 |
| Country: Number of subjects enrolled | Taiwan: 39 |
| Country: Number of subjects enrolled | United Kingdom: 13 |
| Country: Number of subjects enrolled | United States: 146 |
| Worldwide total number of subjects | 821 |
| EEA total number of subjects | 170 |

Notes:

| Subjects enrolled per age group | |
|---|-----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 1 |
| Adults (18-64 years) | 789 |
| From 65 to 84 years | 31 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

As only year of birth was collected on case report form, for one participant, age at enrollment was calculated as 17 years old, using the imputed day and month of "01Jul ". Therefore, not necessarily indicating the participant's actual age.

Pre-assignment

Screening details:

One investigational site with seven participants was excluded from analysis due to confirmed misconduct.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator |

Arms

| | |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes |
| Arm title | Placebo |

Arm description:

Participants received two placebo tablets: one matching 4 mg Baricitinib and one matching 2 mg Baricitinib administered orally every day (QD) for 52 weeks.

| | |
|--|----------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants received two placebo tablets: one matching 4 mg Baricitinib and one matching 2 mg Baricitinib administered orally QD for 52 weeks.

| | |
|------------------|------------------|
| Arm title | 2 mg Baricitinib |
|------------------|------------------|

Arm description:

Participants received one 2 mg Baricitinib tablet and one placebo tablet matching 4 mg Baricitinib administered orally QD for 52 weeks.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | Baricitinib |
| Investigational medicinal product code | |
| Other name | LY3009104 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants received one 2 mg Baricitinib tablet and one placebo tablet matching 4 mg Baricitinib administered orally QD for 52 weeks.

| | |
|------------------|------------------|
| Arm title | 4 mg Baricitinib |
|------------------|------------------|

Arm description:

Participants received one 4 mg Baricitinib tablet and one placebo tablet matching 2 mg Baricitinib administered orally every day (QD) for 52 weeks.

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|-------------|
| Investigational medicinal product name | Baricitinib |
| Investigational medicinal product code | |
| Other name | LY3009104 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants received one 4 mg Baricitinib tablet and one placebo tablet matching 2 mg Baricitinib administered orally every day (QD) for 52 weeks.

| | |
|------------------|---|
| Arm title | Placebo Maximum Extended Enrollment (MEE) |
|------------------|---|

Arm description:

Participants received two placebo tablets: one matching 4 mg Baricitinib and one matching 2 mg Baricitinib administered orally QD for 52 weeks.

| | |
|--|----------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants received two placebo tablets: one matching 4 mg Baricitinib and one matching 2 mg Baricitinib administered orally QD for 52 weeks.

| | |
|------------------|------------------------|
| Arm title | 2 mg Baricitinib (MEE) |
|------------------|------------------------|

Arm description:

Participants received one 2 mg Baricitinib tablet and 1 placebo tablet matching 4 mg Baricitinib administered QD for 52 weeks.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | Baricitinib |
| Investigational medicinal product code | |
| Other name | LY3009104 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants received one 2 mg Baricitinib tablet and 1 placebo tablet matching 4 mg Baricitinib administered QD for 52 weeks.

| | |
|------------------|------------------------|
| Arm title | 4 mg Baricitinib (MEE) |
|------------------|------------------------|

Arm description:

Participants received one 4 mg Baricitinib tablet and one placebo tablet matching 2 mg Baricitinib administered orally QD for 52 weeks.

| | |
|--|--------------|
| Arm type | Experimental |
| Investigational medicinal product name | Baricitinib |
| Investigational medicinal product code | |
| Other name | LY3009104 |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

Participants received one 4 mg Baricitinib tablet and one placebo tablet matching 2 mg Baricitinib administered orally QD for 52 weeks.

| Number of subjects in period 1 | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|--|---------|------------------|------------------|
| Started | 253 | 255 | 252 |
| Received at Least One Dose of Study Drug | 253 | 255 | 252 |
| Completed | 200 | 210 | 206 |
| Not completed | 53 | 45 | 46 |
| Adverse event, serious fatal | 1 | 1 | - |
| Consent withdrawn by subject | 12 | 12 | 15 |
| Physician decision | 2 | - | - |
| Adverse event, non-fatal | 17 | 21 | 9 |
| Due to Epidemic/Pandemic | 4 | 2 | 5 |
| Protocol Deviation | 1 | 1 | - |
| Pregnancy | 1 | - | 4 |
| Protocol Violation | 1 | - | 2 |
| Study Terminated by Sponsor | - | - | - |
| Lost to follow-up | 1 | 2 | 3 |
| Lack of efficacy | 13 | 6 | 8 |

| Number of subjects in period 1 | Placebo Maximum Extended Enrollment (MEE) | 2 mg Baricitinib (MEE) | 4 mg Baricitinib (MEE) |
|--|---|------------------------|------------------------|
| Started | 21 | 20 | 20 |
| Received at Least One Dose of Study Drug | 21 | 20 | 20 |
| Completed | 5 | 5 | 6 |
| Not completed | 16 | 15 | 14 |
| Adverse event, serious fatal | - | - | - |
| Consent withdrawn by subject | 2 | - | 2 |
| Physician decision | - | 1 | - |
| Adverse event, non-fatal | - | - | - |
| Due to Epidemic/Pandemic | - | - | - |
| Protocol Deviation | - | - | - |
| Pregnancy | - | - | - |
| Protocol Violation | - | - | - |
| Study Terminated by Sponsor | 10 | 9 | 11 |
| Lost to follow-up | - | - | - |
| Lack of efficacy | 4 | 5 | 1 |

Baseline characteristics

Reporting groups

| | |
|---|---|
| Reporting group title | Placebo |
| Reporting group description: | |
| Participants received two placebo tablets: one matching 4 mg Baricitinib and one matching 2 mg Baricitinib administered orally every day (QD) for 52 weeks. | |
| Reporting group title | 2 mg Baricitinib |
| Reporting group description: | |
| Participants received one 2 mg Baricitinib tablet and one placebo tablet matching 4 mg Baricitinib administered orally QD for 52 weeks. | |
| Reporting group title | 4 mg Baricitinib |
| Reporting group description: | |
| Participants received one 4 mg Baricitinib tablet and one placebo tablet matching 2 mg Baricitinib administered orally every day (QD) for 52 weeks. | |
| Reporting group title | Placebo Maximum Extended Enrollment (MEE) |
| Reporting group description: | |
| Participants received two placebo tablets: one matching 4 mg Baricitinib and one matching 2 mg Baricitinib administered orally QD for 52 weeks. | |
| Reporting group title | 2 mg Baricitinib (MEE) |
| Reporting group description: | |
| Participants received one 2 mg Baricitinib tablet and 1 placebo tablet matching 4 mg Baricitinib administered QD for 52 weeks. | |
| Reporting group title | 4 mg Baricitinib (MEE) |
| Reporting group description: | |
| Participants received one 4 mg Baricitinib tablet and one placebo tablet matching 2 mg Baricitinib administered orally QD for 52 weeks. | |

| Reporting group values | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|---|---------|------------------|------------------|
| Number of subjects | 253 | 255 | 252 |
| Age categorical | | | |
| Units: Subjects | | | |
| Age continuous | | | |
| Analysis Population Description (APD): All randomized participants who receive at least one dose of study drug. | | | |
| Units: years | | | |
| arithmetic mean | 42.00 | 42.90 | 41.50 |
| standard deviation | ± 11.98 | ± 12.44 | ± 12.88 |
| Gender categorical | | | |
| APD: All randomized participants who receive at least one dose of study drug. | | | |
| Units: Subjects | | | |
| Female | 237 | 238 | 237 |
| Male | 16 | 17 | 15 |
| Ethnicity (NIH/OMB) | | | |
| APD: All randomized participants who receive at least one dose of study drug. | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 4 | 13 | 11 |
| Not Hispanic or Latino | 42 | 35 | 38 |
| Unknown or Not Reported | 207 | 207 | 203 |
| Race (NIH/OMB) | | | |

| | | | |
|---|-----|-----|-----|
| APD: All randomized participants who receive at least one dose of study drug. | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 12 | 15 | 7 |
| Asian | 33 | 39 | 34 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 36 | 23 | 30 |
| White | 168 | 172 | 177 |
| More than one race | 1 | 2 | 0 |
| Unknown or Not Reported | 3 | 4 | 4 |
| Region of Enrollment | | | |
| APD: All randomized participants who receive at least one dose of study drug. | | | |
| Units: Subjects | | | |
| Australia | 10 | 9 | 12 |
| Austria | 0 | 1 | 2 |
| Belgium | 2 | 1 | 1 |
| Brazil | 38 | 22 | 23 |
| China | 16 | 21 | 18 |
| Croatia | 5 | 3 | 2 |
| Czechia | 18 | 11 | 9 |
| Germany | 14 | 14 | 17 |
| Greece | 4 | 9 | 5 |
| Hungary | 13 | 18 | 19 |
| Israel | 1 | 3 | 4 |
| Mexico | 36 | 51 | 49 |
| Netherlands | 0 | 1 | 1 |
| Russia | 26 | 25 | 20 |
| Switzerland | 3 | 2 | 3 |
| Taiwan | 15 | 11 | 13 |
| United Kingdom | 5 | 4 | 4 |
| United States | 47 | 49 | 50 |

| Reporting group values | Placebo Maximum Extended Enrollment (MEE) | 2 mg Baricitinib (MEE) | 4 mg Baricitinib (MEE) |
|-------------------------------|---|------------------------|------------------------|
| Number of subjects | 21 | 20 | 20 |
| Age categorical | | | |
| Units: Subjects | | | |

| | | | |
|---|---------|---------|--------|
| Age continuous | | | |
| Analysis Population Description (APD): All randomized participants who receive at least one dose of study drug. | | | |
| Units: years | | | |
| arithmetic mean | 32.90 | 37.70 | 34.60 |
| standard deviation | ± 10.83 | ± 11.38 | ± 8.31 |
| Gender categorical | | | |
| APD: All randomized participants who receive at least one dose of study drug. | | | |
| Units: Subjects | | | |
| Female | 20 | 19 | 20 |
| Male | 1 | 1 | 0 |
| Ethnicity (NIH/OMB) | | | |
| APD: All randomized participants who receive at least one dose of study drug. | | | |
| Units: Subjects | | | |

| | | | |
|---|----|----|----|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 0 | 0 | 0 |
| Unknown or Not Reported | 21 | 20 | 20 |
| Race (NIH/OMB) | | | |
| APD: All randomized participants who receive at least one dose of study drug. | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 21 | 20 | 20 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment | | | |
| APD: All randomized participants who receive at least one dose of study drug. | | | |
| Units: Subjects | | | |
| Australia | 0 | 0 | 0 |
| Austria | 0 | 0 | 0 |
| Belgium | 0 | 0 | 0 |
| Brazil | 0 | 0 | 0 |
| China | 21 | 20 | 20 |
| Croatia | 0 | 0 | 0 |
| Czechia | 0 | 0 | 0 |
| Germany | 0 | 0 | 0 |
| Greece | 0 | 0 | 0 |
| Hungary | 0 | 0 | 0 |
| Israel | 0 | 0 | 0 |
| Mexico | 0 | 0 | 0 |
| Netherlands | 0 | 0 | 0 |
| Russia | 0 | 0 | 0 |
| Switzerland | 0 | 0 | 0 |
| Taiwan | 0 | 0 | 0 |
| United Kingdom | 0 | 0 | 0 |
| United States | 0 | 0 | 0 |

| | | | |
|-------------------------------|-------|--|--|
| Reporting group values | Total | | |
| Number of subjects | 821 | | |
| Age categorical | | | |
| Units: Subjects | | | |

| | | | |
|---|-----|--|--|
| Age continuous | | | |
| Analysis Population Description (APD): All randomized participants who receive at least one dose of study drug. | | | |
| Units: years | | | |
| arithmetic mean | | | |
| standard deviation | - | | |
| Gender categorical | | | |
| APD: All randomized participants who receive at least one dose of study drug. | | | |
| Units: Subjects | | | |
| Female | 771 | | |
| Male | 50 | | |

| | | | |
|---|-----|--|--|
| Ethnicity (NIH/OMB) | | | |
| APD: All randomized participants who receive at least one dose of study drug. | | | |
| Units: Subjects | | | |
| Hispanic or Latino | 28 | | |
| Not Hispanic or Latino | 115 | | |
| Unknown or Not Reported | 678 | | |
| Race (NIH/OMB) | | | |
| APD: All randomized participants who receive at least one dose of study drug. | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 34 | | |
| Asian | 167 | | |
| Native Hawaiian or Other Pacific Islander | 0 | | |
| Black or African American | 89 | | |
| White | 517 | | |
| More than one race | 3 | | |
| Unknown or Not Reported | 11 | | |
| Region of Enrollment | | | |
| APD: All randomized participants who receive at least one dose of study drug. | | | |
| Units: Subjects | | | |
| Australia | 31 | | |
| Austria | 3 | | |
| Belgium | 4 | | |
| Brazil | 83 | | |
| China | 116 | | |
| Croatia | 10 | | |
| Czechia | 38 | | |
| Germany | 45 | | |
| Greece | 18 | | |
| Hungary | 50 | | |
| Israel | 8 | | |
| Mexico | 136 | | |
| Netherlands | 2 | | |
| Russia | 71 | | |
| Switzerland | 8 | | |
| Taiwan | 39 | | |
| United Kingdom | 13 | | |
| United States | 146 | | |

End points

End points reporting groups

| | |
|---|---|
| Reporting group title | Placebo |
| Reporting group description: Participants received two placebo tablets: one matching 4 mg Baricitinib and one matching 2 mg Baricitinib administered orally every day (QD) for 52 weeks. | |
| Reporting group title | 2 mg Baricitinib |
| Reporting group description: Participants received one 2 mg Baricitinib tablet and one placebo tablet matching 4 mg Baricitinib administered orally QD for 52 weeks. | |
| Reporting group title | 4 mg Baricitinib |
| Reporting group description: Participants received one 4 mg Baricitinib tablet and one placebo tablet matching 2 mg Baricitinib administered orally every day (QD) for 52 weeks. | |
| Reporting group title | Placebo Maximum Extended Enrollment (MEE) |
| Reporting group description: Participants received two placebo tablets: one matching 4 mg Baricitinib and one matching 2 mg Baricitinib administered orally QD for 52 weeks. | |
| Reporting group title | 2 mg Baricitinib (MEE) |
| Reporting group description: Participants received one 2 mg Baricitinib tablet and 1 placebo tablet matching 4 mg Baricitinib administered QD for 52 weeks. | |
| Reporting group title | 4 mg Baricitinib (MEE) |
| Reporting group description: Participants received one 4 mg Baricitinib tablet and one placebo tablet matching 2 mg Baricitinib administered orally QD for 52 weeks. | |
| Subject analysis set title | 2 mg Baricitinib |
| Subject analysis set type | Modified intention-to-treat |
| Subject analysis set description: Participants received one Baricitinib 2 mg tablet and one placebo tablet matching Baricitinib 4 mg administered orally QD for 52 weeks. | |
| Subject analysis set title | 4 mg Baricitinib |
| Subject analysis set type | Modified intention-to-treat |
| Subject analysis set description: Participants received one Baricitinib 4 mg tablet and one placebo tablet matching baricitinib 2 mg administered orally QD for 52 weeks. | |

Primary: Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (4 mg Baricitinib)

| | |
|--|--|
| End point title | Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (4 mg Baricitinib) ^[1] |
| End point description: SRI-4 response defined as 1)greater than or equal to (\geq) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of ≥ 0.3 from baseline on a 0-3 visual analogue scale). SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assess disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe). | |
| End point type | Primary |

End point timeframe:

Week 52

APD: All randomized participants who received at least one dose of study drug (modified intent-to-treat (mITT) population). Missing data was imputed using the hybrid imputation method [nonresponder imputation (NRI) + multiple imputation (MI)].

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The analysis is planned only for these reporting arms.

As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.

| End point values | Placebo | 4 mg Baricitinib | | |
|-----------------------------------|-----------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 253 | 252 | | |
| Units: percentage of participants | | | | |
| number (not applicable) | 45.9 | 56.7 | | |

Statistical analyses

| | |
|---|----------------------------|
| Statistical analysis title | SRI-4 Response (4 mg) |
| Comparison groups | Placebo v 4 mg Baricitinib |
| Number of subjects included in analysis | 505 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.016 |
| Method | Regression, Logistic |
| Parameter estimate | Odds ratio (OR) |
| Point estimate | 1.57 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 1.09 |
| upper limit | 2.27 |

Secondary: Percentage of Participants Achieving SRI-4 Response - 2 mg Baricitinib

| | |
|-----------------|---|
| End point title | Percentage of Participants Achieving SRI-4 Response - 2 mg Baricitinib ^[2] |
|-----------------|---|

End point description:

SRI-4 response defined as 1)greater than or equal to (\geq) 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score 2)no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and 3)no worsening in Physician Global Assessment (PGA) of Disease Activity (worsening defined as an increase of ≥ 0.3 from baseline on a 0-3 visual analogue scale).

SLEDAI-2K assessment consists of 24 items with total score of 0(no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms,or laboratory parameters related to Systemic Lupus Erythematosus (SLE),divided into 9 organ systems. For each organ system A=severe disease,B=moderate disease,C=mild stable disease,D=inactive,but previously active,E=inactive and never affected. PGA assess disease activity on a visual analogue scale from 0 to 3 (1=mild, 2=moderate, 3=severe).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 52

APD: All randomized participants who receive at least one dose of study drug (mITT population). Missing data was imputed using the hybrid imputation method [nonresponder imputation (NRI) + multiple imputation (MI)].

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: The analysis is planned only for these reporting arms.

As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.

| End point values | Placebo | 2 mg Baricitinib | | |
|-----------------------------------|-----------------|------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 253 | 255 | | |
| Units: percentage of participants | | | | |
| number (not applicable) | 45.9 | 49.8 | | |

Statistical analyses

| | |
|---|----------------------------|
| Statistical analysis title | SRI-4 Response (2 mg) |
| Comparison groups | Placebo v 2 mg Baricitinib |
| Number of subjects included in analysis | 508 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.47 |
| Method | Regression, Logistic |
| Parameter estimate | Odds ratio (OR) |
| Point estimate | 1.14 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.79 |
| upper limit | 1.65 |

Secondary: Percentage of Participants Achieving a Lupus Low Disease Activity State (LLDAS)

| | |
|-----------------|--|
| End point title | Percentage of Participants Achieving a Lupus Low Disease Activity State (LLDAS) ^[3] |
|-----------------|--|

End point description:

The LLDAS is a composite measure designed to identify patients achieving a state of low disease activity. The LLDAS response criteria were: (1) SLEDAI-2K ≤ 4 , with no activity in major organ systems (CNS, vascular, renal, cardiorespiratory and constitutional); where "no activity" is defined as all items of SLEDAI-2K within these major organ systems equal to 0. (2) no new features of lupus disease activity compared to previous occurred visit, where the "new feature" is defined as any of the SLEDAI-2K 24 items changed from 0 to greater than 0; (3) PGA (scale 0-3), ≤ 1 ; (4) current prednisolone (or equivalent) dose ≤ 7.5 mg daily.

APD: All randomized participants who receive at least one dose of study drug (mITT population). Missing data was imputed using the hybrid imputation method [nonresponder imputation (NRI) + multiple imputation (MI)].

| | |
|---|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Week 52 | |
| Notes: | |
| [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups. | |

| End point values | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | |
|-----------------------------------|-----------------|------------------|------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 253 | 255 | 252 | |
| Units: percentage of participants | | | | |
| number (not applicable) | 26.2 | 25.7 | 29.7 | |

Statistical analyses

| Statistical analysis title | Lupus Low Disease Activity State (2 mg) |
|---|---|
| Comparison groups | Placebo v 2 mg Baricitinib |
| Number of subjects included in analysis | 508 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.839 |
| Method | Regression, Logistic |
| Parameter estimate | Odds ratio (OR) |
| Point estimate | 0.96 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.63 |
| upper limit | 1.45 |

| Statistical analysis title | Lupus Low Disease Activity State (4 mg) |
|---|---|
| Comparison groups | Placebo v 4 mg Baricitinib |
| Number of subjects included in analysis | 505 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.391 |
| Method | Regression, Logistic |
| Parameter estimate | Odds ratio (OR) |
| Point estimate | 1.19 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.8 |
| upper limit | 1.79 |

Secondary: Time to First Severe Flare

| | |
|-----------------|---|
| End point title | Time to First Severe Flare ^[4] |
|-----------------|---|

End point description:

Time to first severe flare was analyzed using a Cox proportional hazards model with treatment group, baseline disease activity (Systemic Lupus Erythematosus Disease Activity Index 2000 [SLEDAI-2K] <10; SLEDAI-2K ≥10), baseline corticosteroid dose (<10 mg/day; ≥10 mg/day prednisone or equivalent), and region fitted as explanatory variables. Participants who did not have severe flare during the flare exposure time period were censored at the end of the flare exposure time.

APD: All randomized participants who receive at least one dose of study drug (mITT population). 9999=Data Not Available (N/A) as < 50% of participants experienced first flare, median was not reached, and 95% confidence interval could not be calculated.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline to Week 52

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.

| End point values | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | |
|----------------------------------|---------------------|---------------------|---------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 253 | 255 | 252 | |
| Units: weeks | | | | |
| median (confidence interval 95%) | 9999 (9999 to 9999) | 9999 (9999 to 9999) | 9999 (9999 to 9999) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Whose Average Prednisone Dose Had Been Reduced by ≥25% From Baseline to ≤7.5 mg/Day During Weeks 40 Through 52 in Participants Receiving Greater Than 7.5 mg/Day at Baseline

| | |
|-----------------|--|
| End point title | Percentage of Participants Whose Average Prednisone Dose Had Been Reduced by ≥25% From Baseline to ≤7.5 mg/Day During Weeks 40 Through 52 in Participants Receiving Greater Than 7.5 mg/Day at Baseline ^[5] |
|-----------------|--|

End point description:

For the analysis of steroid use, steroid dosages were converted to a prednisone equivalent in mg. A responder was defined as having a prednisone reduction by ≥25% from Baseline to ≤7.5 mg/day during Weeks 40 through 52.

APD: All randomized participants who received at least one dose of study drug (mITT population) and received >7.5 mg prednisone at baseline. Missing data was imputed using the hybrid imputation method [NRI + mLOCF (modified last observation carried forward)].

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Week 40 through Week 52

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.

| End point values | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | |
|-----------------------------------|-----------------|------------------|------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 117 | 106 | 106 | |
| Units: percentage of participants | | | | |
| number (not applicable) | 30.8 | 29.2 | 34.0 | |

Statistical analyses

| | |
|---|----------------------------------|
| Statistical analysis title | Prednisone Dose Reduction (2 mg) |
| Comparison groups | Placebo v 2 mg Baricitinib |
| Number of subjects included in analysis | 223 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.82 |
| Method | Regression, Logistic |
| Parameter estimate | Odds ratio (OR) |
| Point estimate | 0.94 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.53 |
| upper limit | 1.66 |

| | |
|---|-----------------------------|
| Statistical analysis title | Prednisone Reduction (4 mg) |
| Comparison groups | Placebo v 4 mg Baricitinib |
| Number of subjects included in analysis | 223 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.565 |
| Method | Regression, Logistic |
| Parameter estimate | Odds ratio (OR) |
| Point estimate | 1.18 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.67 |
| upper limit | 2.08 |

Secondary: Change from Baseline in Worst Pain Numeric Rating Scale (NRS)

| | |
|-----------------|--|
| End point title | Change from Baseline in Worst Pain Numeric Rating Scale (NRS) ^[6] |
|-----------------|--|

End point description:

Participants assessed their worst pain in the last 24 hours on an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The average worst daily pain score was calculated as the mean of the scores over the last 7 days prior to each assessment time point. Higher score indicated severe pain. Least Squares (LS) mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K <10; ≥10), baseline corticosteroid dose (<10 mg/day; ≥10 mg/day prednisone or equivalent), region (North America, Central/South, America/Mexico, Europe, Asia Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Week 52

APD: All randomized participants who received at least 1 dose of study drug (mITT population) and had baseline and post-baseline values at the specified time point. Missing data was imputed using the hybrid imputation method NRI + MMRM.

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.

| End point values | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | |
|-------------------------------------|-----------------|------------------|------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 173 | 173 | 182 | |
| Units: score on a scale | | | | |
| least squares mean (standard error) | -1.62 (± 0.15) | -1.73 (± 0.15) | -1.71 (± 0.15) | |

Statistical analyses

| | |
|---|---|
| Statistical analysis title | Change from Baseline in Worst Pain NRS (2 mg) |
| Comparison groups | Placebo v 2 mg Baricitinib |
| Number of subjects included in analysis | 346 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.598 |
| Method | Mixed models analysis |
| Parameter estimate | LS Mean Difference Final Values |
| Point estimate | -0.11 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.52 |
| upper limit | 0.3 |
| Variability estimate | Standard error of the mean |
| Dispersion value | 0.21 |

| | |
|---|---|
| Statistical analysis title | Change from Baseline in Worst Pain NRS (4 mg) |
| Comparison groups | Placebo v 4 mg Baricitinib |
| Number of subjects included in analysis | 355 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.674 |
| Method | Mixed models analysis |
| Parameter estimate | LS Mean Difference Final Values |
| Point estimate | -0.09 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.5 |
| upper limit | 0.32 |
| Variability estimate | Standard error of the mean |
| Dispersion value | 0.21 |

Secondary: Change from Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Total Score

| | |
|-----------------|---|
| End point title | Change from Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Total Score ^[7] |
|-----------------|---|

End point description:

FACIT-Fatigue score calculated according to a 13-item questionnaire that assess self reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status. Least Squares (LS) mean was calculated using MMRM analysis with treatment, baseline disease activity (total SLEDAI-2K <10; >=10), baseline corticosteroid dose (<10 mg/day; >= 10 mg/day prednisone or equivalent), region (North America, Central/South, America/Mexico, Europe, Asia Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Week 52

APD: All randomized participants who received at least one dose of study drug (mITT population) and had baseline and post-baseline values at the specified time point. Missing data was imputed using hybrid the imputation method NRI+MMRM.

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.

| End point values | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | |
|-------------------------------------|-----------------|------------------|------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 188 | 201 | 204 | |
| Units: score on a scale | | | | |
| least squares mean (standard error) | 7.44 (± 0.62) | 7.46 (± 0.60) | 7.08 (± 0.61) | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | Change from Baseline in FACIT-Fatigue (2 mg) |
| Comparison groups | Placebo v 2 mg Baricitinib |
| Number of subjects included in analysis | 389 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.979 |
| Method | Mixed models analysis |
| Parameter estimate | LS Mean Difference Final Values |
| Point estimate | 0.02 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.65 |
| upper limit | 1.7 |
| Variability estimate | Standard error of the mean |
| Dispersion value | 0.85 |

| | |
|---|--|
| Statistical analysis title | Change from Baseline in FACIT-Fatigue (4 mg) |
| Comparison groups | Placebo v 4 mg Baricitinib |
| Number of subjects included in analysis | 392 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.678 |
| Method | Mixed models analysis |
| Parameter estimate | LS Mean Difference Final Values |
| Point estimate | -0.36 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.03 |
| upper limit | 1.32 |
| Variability estimate | Standard error of the mean |
| Dispersion value | 0.86 |

Secondary: Percentage of Participants with Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Total Activity Score ≥ 10 at Baseline with $\geq 50\%$ Reduction in CLASI Total Activity Score

| | |
|-----------------|--|
| End point title | Percentage of Participants with Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Total Activity Score ≥ 10 at Baseline with $\geq 50\%$ Reduction in CLASI Total Activity Score ^[8] |
|-----------------|--|

End point description:

The CLASI is a single-page tool that separately quantifies disease activity and damage. For the activity score, points are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and inflammatory alopecia. The total score represents the sum of the individual scores and ranges from 0 to 70. Higher scores are awarded for more severe manifestations.

APD: All randomized participants who received at least one dose of study drug (mITT population) and

had baseline CLASI score of ≥ 10 . Missing data was imputed using NRI method.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 52

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.

| End point values | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | |
|-----------------------------------|-----------------|------------------|------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 49 | 46 | 43 | |
| Units: percentage of participants | | | | |
| number (not applicable) | 49.0 | 54.3 | 55.8 | |

Statistical analyses

| | |
|---|-------------------------------------|
| Statistical analysis title | 50% Reduction in CLASI Score (2 mg) |
| Comparison groups | Placebo v 2 mg Baricitinib |
| Number of subjects included in analysis | 95 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.965 |
| Method | Regression, Logistic |
| Parameter estimate | Odds ratio (OR) |
| Point estimate | 1.02 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.43 |
| upper limit | 2.42 |

| | |
|---|-------------------------------------|
| Statistical analysis title | 50% Reduction in CLASI Score (4 mg) |
| Comparison groups | Placebo v 4 mg Baricitinib |
| Number of subjects included in analysis | 92 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.661 |
| Method | Regression, Logistic |
| Parameter estimate | Odds ratio (OR) |
| Point estimate | 1.22 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.51 |
| upper limit | 2.92 |

Secondary: Change from Baseline in Tender Joint Count

| | |
|---|---|
| End point title | Change from Baseline in Tender Joint Count ^[9] |
| End point description: The number of tender and painful joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as tender or not tender. LS mean was calculated using Mixed Model Repeated Measures (MMRM) analysis with treatment, baseline disease activity (total SLEDAI-2K <10; ≥10), baseline corticosteroid dose (<10 mg/day; ≥10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction. APD: All randomized participants who receive at least one dose of study drug (mITT population) and had baseline and post-baseline values at specified time point. | |
| End point type | Secondary |
| End point timeframe: Baseline, Week 52 | |

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.

| End point values | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | |
|-------------------------------------|-----------------|------------------|------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 183 | 198 | 195 | |
| Units: tender joint count | | | | |
| least squares mean (standard error) | -7.50 (± 0.312) | -7.26 (± 0.305) | -7.94 (± 0.307) | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | Change from Baseline Tender Joint Count (2 mg) |
| Comparison groups | Placebo v 2 mg Baricitinib |
| Number of subjects included in analysis | 381 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.578 |
| Method | Mixed models analysis |
| Parameter estimate | LS Mean Difference Final Values |
| Point estimate | 0.24 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.61 |
| upper limit | 1.08 |
| Variability estimate | Standard error of the mean |
| Dispersion value | 0.43 |

| | |
|---|--|
| Statistical analysis title | Change from Baseline Tender Joint Count (4 mg) |
| Comparison groups | Placebo v 4 mg Baricitinib |
| Number of subjects included in analysis | 378 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.309 |
| Method | Mixed models analysis |
| Parameter estimate | LS Mean Difference Final Values |
| Point estimate | -0.44 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.29 |
| upper limit | 0.41 |
| Variability estimate | Standard error of the mean |
| Dispersion value | 0.433 |

Secondary: Change from Baseline in Swollen Joint Count

| | |
|---|---|
| End point title | Change from Baseline in Swollen Joint Count ^[10] |
| End point description: | |
| <p>The number of swollen joints is determined by examination of 28 joints (14 on each side) which include: the 2 shoulders, the 2 elbows, the 2 wrists, the 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. The joints are assessed and classified as swollen or not swollen. LS mean was calculated using MMRM analysis with treatment, baseline disease activity (total SLEDAI-2K <10; ≥10), baseline corticosteroid dose (<10 mg/day; ≥10 mg/day prednisone or equivalent), region (North America, Central/South America/Mexico, Europe, Asia and Rest of World), visit (as categorical variable), baseline value, treatment-by-visit interaction, and baseline value-by-visit interaction.</p> <p>APD: All randomized participants who receive at least one dose of study drug (mITT population) and had baseline and post-baseline values at the specified time point.</p> | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline, Week 52 | |

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.

| End point values | Placebo | 2 mg Baricitinib | 4 mg Baricitinib | |
|-------------------------------------|-----------------|------------------|------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 183 | 198 | 195 | |
| Units: swollen joint count | | | | |
| least squares mean (standard error) | -5.37 (± 0.201) | -5.67 (± 0.196) | -5.81 (± 0.198) | |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | Change from Baseline in Swollen Joint Count (2 mg) |
| Comparison groups | Placebo v 2 mg Baricitinib |
| Number of subjects included in analysis | 381 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.287 |
| Method | Mixed models analysis |
| Parameter estimate | LS Mean Difference Final Values |
| Point estimate | -0.29 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.84 |
| upper limit | 0.25 |
| Variability estimate | Standard error of the mean |
| Dispersion value | 0.277 |

| | |
|---|--|
| Statistical analysis title | Change from Baseline in Swollen Joint Count (4 mg) |
| Comparison groups | Placebo v 4 mg Baricitinib |
| Number of subjects included in analysis | 378 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.113 |
| Method | Mixed models analysis |
| Parameter estimate | LS Mean Difference Final Values |
| Point estimate | -0.44 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.99 |
| upper limit | 0.11 |
| Variability estimate | Standard error of the mean |
| Dispersion value | 0.278 |

Secondary: Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUC_T, ss)

| | |
|-----------------|--|
| End point title | Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUC _T , ss) |
|-----------------|--|

End point description:

PK: Area Under the Concentration-Time Curve of Baricitinib at Steady State (AUC_{T, ss}) was evaluated using population PK approach.

APD: All randomized participants who received at least one dose of study drug and had evaluable PK data. As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 0 (Baseline): 15 minutes (min) and 60 min postdose; Week 4: 2 to 4 hours (hr) postdose; Week 8: 4 to 6 hr postdose; Week 12 and Week 16 predose

| End point values | 2 mg Baricitinib | 4 mg Baricitinib | | |
|---|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 248 | 220 | | |
| Units: hour*nanograms per milliliter (h*ng/mL) | | | | |
| geometric mean (geometric coefficient of variation) | 256 (± 52) | 502 (± 52) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Population PK: Maximum Observed Drug Concentration at Steady State (C_{max,ss})

| | |
|-----------------|---|
| End point title | Population PK: Maximum Observed Drug Concentration at Steady State (C _{max,ss}) |
|-----------------|---|

End point description:

Population PK: Maximum Observed Drug Concentration at Steady State (C_{max,ss}) was evaluated using population PK approach.

APD: All randomized participants who received at least one dose of study drug and had evaluable PK data. As pre-specified in the analysis plan, outcome measures will not be reported for the MEE arms/groups but only for the main global study arms/groups.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 0 (Baseline): 15 minutes (min) and 60 min postdose; Week 4: 2 to 4 hours (hr) postdose; Week 8: 4 to 6 hr postdose; Week 12 and Week 16 predose

| End point values | 2 mg Baricitinib | 4 mg Baricitinib | | |
|---|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 248 | 220 | | |
| Units: nanograms per milliliter (ng/mL) | | | | |
| geometric mean (geometric coefficient of variation) | 26.7 (± 24) | 53.0 (± 23) | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline through Follow-up (Up to 56 Weeks)

Adverse event reporting additional description:

All randomized participants who received at least one dose of investigational product and who did not discontinue from the study for the reason "Lost to Follow-up" at the first postbaseline visit. Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 24.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

Participants received two placebo tablets: one matching baricitinib 4 mg and one matching baricitinib 2 mg administered orally QD for 52 weeks.

| | |
|-----------------------|------------------|
| Reporting group title | 2 mg Baricitinib |
|-----------------------|------------------|

Reporting group description:

Participants received one Baricitinib 2 mg tablet and one placebo tablet matching Baricitinib 4 mg administered QD for 52 weeks.

| | |
|-----------------------|------------------|
| Reporting group title | 4 mg Baricitinib |
|-----------------------|------------------|

Reporting group description:

Participants received one Baricitinib 4 mg tablet and one placebo tablet matching baricitinib 2 mg administered orally QD for 52 weeks.

| | |
|-----------------------|---|
| Reporting group title | Placebo Maximum Extended Enrollment (MEE) |
|-----------------------|---|

Reporting group description:

Participants received two placebo tablets: one matching baricitinib 4 mg and one matching baricitinib 2 mg administered orally QD for 52 weeks

| | |
|-----------------------|------------------------|
| Reporting group title | 2 mg Baricitinib (MEE) |
|-----------------------|------------------------|

Reporting group description:

Participants received one Baricitinib 2 mg tablet and 1 placebo tablet matching Baricitinib 4 mg administered QD for 52 weeks.

| | |
|-----------------------|------------------------|
| Reporting group title | 4 mg Baricitinib (MEE) |
|-----------------------|------------------------|

Reporting group description:

Participants received one Baricitinib 4 mg tablet and one placebo tablet matching baricitinib 2 mg administered orally QD for 52 weeks.

| Serious adverse events | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|---|------------------|-------------------|-------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 19 / 253 (7.51%) | 27 / 255 (10.59%) | 31 / 252 (12.30%) |
| number of deaths (all causes) | 1 | 1 | 0 |
| number of deaths resulting from adverse events | 0 | 1 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) adenocarcinoma of the cervix alternative dictionary used: | | | |

| | | | | |
|---|-----------------|-----------------|-----------------|--|
| MedDRA 24.0 | | | | |
| subjects affected / exposed ^[1] | 1 / 237 (0.42%) | 0 / 238 (0.00%) | 0 / 237 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 | |
| burkitt's lymphoma | | | | |
| alternative dictionary used: MedDRA 24.0 | | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 | |
| haemangioma of liver | | | | |
| alternative dictionary used: MedDRA 24.0 | | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 0 / 252 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 | |
| lung carcinoma cell type unspecified stage 0 | | | | |
| alternative dictionary used: MedDRA 24.0 | | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 | |
| melanocytic naevus | | | | |
| alternative dictionary used: MedDRA 24.0 | | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 0 / 255 (0.00%) | 0 / 252 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 | |
| papillary thyroid cancer | | | | |
| alternative dictionary used: MedDRA 24.0 | | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 | |
| uterine leiomyoma | | | | |
| alternative dictionary used: MedDRA 24.0 | | | | |

| | | | |
|--|-----------------|-----------------|-----------------|
| subjects affected / exposed ^[2] | 1 / 237 (0.42%) | 0 / 238 (0.00%) | 1 / 237 (0.42%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| deep vein thrombosis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| vasculitis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 0 / 255 (0.00%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pregnancy, puerperium and perinatal conditions | | | |
| abortion spontaneous | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed ^[3] | 0 / 237 (0.00%) | 0 / 238 (0.00%) | 1 / 237 (0.42%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| death | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 0 / 255 (0.00%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| non-cardiac chest pain | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pyrexia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| drug hypersensitivity | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 0 / 255 (0.00%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| adnexal torsion | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed ^[4] | 0 / 237 (0.00%) | 0 / 238 (0.00%) | 1 / 237 (0.42%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cervical dysplasia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed ^[5] | 0 / 237 (0.00%) | 0 / 238 (0.00%) | 1 / 237 (0.42%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hydrosalpinx | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed ^[6] | 0 / 237 (0.00%) | 1 / 238 (0.42%) | 0 / 237 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ovarian cyst | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed ^[7] | 1 / 237 (0.42%) | 0 / 238 (0.00%) | 0 / 237 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| bronchitis chronic | | | |
| alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pleural effusion alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pleurisy alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pulmonary embolism alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pulmonary hypertension alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders major depression alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 0 / 255 (0.00%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications ankle fracture alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 2 / 252 (0.79%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| device use issue | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 0 / 255 (0.00%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| femur fracture | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 0 / 255 (0.00%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| fibula fracture | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| foot fracture | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tendon rupture | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| acute myocardial infarction | | | |
| alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| arteriosclerosis coronary artery alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| atrial fibrillation alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| coronary artery disease alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| myocardial ischaemia alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pericarditis alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders cerebrovascular accident alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| anaemia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| leukopenia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| neutropenia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| abdominal adhesions | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abdominal pain lower | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| epiploic appendagitis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastric ulcer | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastritis erosive | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| haematochezia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| haemorrhoidal haemorrhage | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| obstructive pancreatitis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| upper gastrointestinal haemorrhage | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|--|-----------------|-----------------|-----------------|
| Hepatobiliary disorders | | | |
| bile duct stone | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis chronic | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholelithiasis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| cutaneous lupus erythematosus | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| dermatitis bullous | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| lupus nephritis | | | |

| | | | |
|--|-----------------|-----------------|-----------------|
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 2 / 255 (0.78%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ureterolithiasis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| arthralgia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 0 / 255 (0.00%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| osteoarthritis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 0 / 255 (0.00%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| osteonecrosis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| spinal stenosis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 0 / 255 (0.00%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| systemic lupus erythematosus | | | |
| alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 253 (0.40%) | 1 / 255 (0.39%) | 4 / 252 (1.59%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| anal abscess | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| appendicitis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| arthritis bacterial | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| atypical pneumonia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bronchitis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| covid-19 | | | |
| alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|--|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| covid-19 pneumonia alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| escherichia urinary tract infection alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastroenteritis alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 1 / 255 (0.39%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| herpes zoster alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| infection alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| laryngitis alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| pneumonia alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 4 / 255 (1.57%) | 2 / 252 (0.79%) |
| occurrences causally related to treatment / all | 0 / 0 | 3 / 5 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pyelonephritis acute alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 0 / 255 (0.00%) | 1 / 252 (0.40%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tubo-ovarian abscess alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed ^[8] | 0 / 237 (0.00%) | 1 / 238 (0.42%) | 0 / 237 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| viral myocarditis alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 0 / 255 (0.00%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| viral pericarditis alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 0 / 255 (0.00%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| dehydration alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 0 / 255 (0.00%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hypoalbuminaemia alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 253 (0.40%) | 0 / 255 (0.00%) | 0 / 252 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| Serious adverse events | Placebo Maximum Extended Enrollment (MEE) | 2 mg Baricitinib (MEE) | 4 mg Baricitinib (MEE) |
|---|---|---------------------------|---------------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 21 (4.76%) | 4 / 20 (20.00%) | 3 / 20 (15.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| adenocarcinoma of the cervix | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed ^[1] | 0 / 20 (0.00%) | 0 / 19 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| burkitt's lymphoma | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| haemangioma of liver | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 1 / 20 (5.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| lung carcinoma cell type unspecified stage 0 | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| melanocytic naevus | | | |
| alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|--|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| papillary thyroid cancer | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| uterine leiomyoma | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed ^[2] | 0 / 20 (0.00%) | 0 / 19 (0.00%) | 1 / 20 (5.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| deep vein thrombosis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| vasculitis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pregnancy, puerperium and perinatal conditions | | | |
| abortion spontaneous | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed ^[3] | 0 / 20 (0.00%) | 0 / 19 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| death | | | |
| alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| non-cardiac chest pain | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pyrexia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| drug hypersensitivity | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| adnexal torsion | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed ^[4] | 0 / 20 (0.00%) | 0 / 19 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cervical dysplasia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed ^[5] | 0 / 20 (0.00%) | 0 / 19 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hydrosalpinx | | | |
| alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed ^[6] | 0 / 20 (0.00%) | 0 / 19 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ovarian cyst | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed ^[7] | 0 / 20 (0.00%) | 0 / 19 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| bronchitis chronic | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pleural effusion | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pleurisy | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pulmonary embolism | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pulmonary hypertension | | | |
| alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 21 (0.00%) | 1 / 20 (5.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| major depression | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| ankle fracture | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| device use issue | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| femur fracture | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| fibula fracture | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| foot fracture | | | |
| alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| tendon rupture | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| acute myocardial infarction | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| arteriosclerosis coronary artery | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| atrial fibrillation | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| coronary artery disease | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| myocardial ischaemia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| pericarditis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nervous system disorders | | | |
| cerebrovascular accident | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| anaemia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| leukopenia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| neutropenia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| abdominal adhesions | | | |
| alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| abdominal pain lower | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| epiploic appendagitis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastric ulcer | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastritis erosive | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| haematochezia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| haemorrhoidal haemorrhage | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|----------------|----------------|----------------|
| obstructive pancreatitis alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| upper gastrointestinal haemorrhage alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| bile duct stone alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholecystitis chronic alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 1 / 20 (5.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| cholelithiasis alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 1 / 20 (5.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| cutaneous lupus erythematosus alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| dermatitis bullous | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| lupus nephritis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 21 (4.76%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| ureterolithiasis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| arthralgia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| osteoarthritis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| osteonecrosis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 21 (0.00%) | 1 / 20 (5.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| spinal stenosis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| systemic lupus erythematosus | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 1 / 20 (5.00%) | 1 / 20 (5.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| anal abscess | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| appendicitis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| arthritis bacterial | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| atypical pneumonia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| bronchitis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| covid-19 | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| covid-19 pneumonia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| escherichia urinary tract infection | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| gastroenteritis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| herpes zoster | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | | |
|--|----------------|----------------|----------------|--|
| infection | | | | |
| alternative dictionary used: MedDRA 24.0 | | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 | |
| laryngitis | | | | |
| alternative dictionary used: MedDRA 24.0 | | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 | |
| pneumonia | | | | |
| alternative dictionary used: MedDRA 24.0 | | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 | |
| pyelonephritis acute | | | | |
| alternative dictionary used: MedDRA 24.0 | | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 | |
| tubo-ovarian abscess | | | | |
| alternative dictionary used: MedDRA 24.0 | | | | |
| subjects affected / exposed ^[8] | 0 / 20 (0.00%) | 0 / 19 (0.00%) | 0 / 20 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 | |
| viral myocarditis | | | | |
| alternative dictionary used: MedDRA 24.0 | | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 | |
| viral pericarditis | | | | |
| alternative dictionary used: MedDRA 24.0 | | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| dehydration | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| hypoalbuminaemia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[6] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[7] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[8] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Placebo | 2 mg Baricitinib | 4 mg Baricitinib |
|--|----------------------------|----------------------------|----------------------------|
| Total subjects affected by non-serious adverse events subjects affected / exposed | 129 / 253 (50.99%) | 144 / 255 (56.47%) | 144 / 252 (57.14%) |
| Vascular disorders hypertension alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) | 10 / 253 (3.95%) 10 | 17 / 255 (6.67%) 18 | 17 / 252 (6.75%) 18 |
| General disorders and administration site conditions chest discomfort alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) | 0 / 253 (0.00%) 0 | 0 / 255 (0.00%) 0 | 4 / 252 (1.59%) 4 |
| Reproductive system and breast disorders prostatitis alternative dictionary used: MedDRA 24.0 subjects affected / exposed ^[9] occurrences (all) | 0 / 16 (0.00%) 0 | 1 / 17 (5.88%) 1 | 0 / 15 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders cough alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) | 7 / 253 (2.77%) 7 | 5 / 255 (1.96%) 5 | 7 / 252 (2.78%) 7 |
| Psychiatric disorders insomnia alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) | 8 / 253 (3.16%) 8 | 4 / 255 (1.57%) 4 | 5 / 252 (1.98%) 6 |
| Investigations alanine aminotransferase increased alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) blood creatine phosphokinase increased alternative dictionary used: MedDRA 24.0 | 7 / 253 (2.77%) 7 | 6 / 255 (2.35%) 8 | 2 / 252 (0.79%) 5 |

| | | | |
|--|-----------------------------------|-----------------------------------|-----------------------------------|
| <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>3 / 253 (1.19%)</p> <p>4</p> | <p>8 / 255 (3.14%)</p> <p>9</p> | <p>14 / 252 (5.56%)</p> <p>20</p> |
| <p>hepatic enzyme increased</p> <p>alternative dictionary used: MedDRA 24.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>1 / 253 (0.40%)</p> <p>1</p> | <p>0 / 255 (0.00%)</p> <p>0</p> | <p>2 / 252 (0.79%)</p> <p>2</p> |
| <p>weight increased</p> <p>alternative dictionary used: MedDRA 24.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>7 / 253 (2.77%)</p> <p>9</p> | <p>5 / 255 (1.96%)</p> <p>5</p> | <p>3 / 252 (1.19%)</p> <p>3</p> |
| <p>Nervous system disorders</p> <p>dizziness</p> <p>alternative dictionary used: MedDRA 24.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>4 / 253 (1.58%)</p> <p>4</p> | <p>1 / 255 (0.39%)</p> <p>1</p> | <p>5 / 252 (1.98%)</p> <p>6</p> |
| <p>headache</p> <p>alternative dictionary used: MedDRA 24.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>25 / 253 (9.88%)</p> <p>26</p> | <p>16 / 255 (6.27%)</p> <p>19</p> | <p>20 / 252 (7.94%)</p> <p>23</p> |
| <p>hypoaesthesia</p> <p>alternative dictionary used: MedDRA 24.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>0 / 253 (0.00%)</p> <p>0</p> | <p>1 / 255 (0.39%)</p> <p>1</p> | <p>2 / 252 (0.79%)</p> <p>2</p> |
| <p>Blood and lymphatic system disorders</p> <p>anaemia</p> <p>alternative dictionary used: MedDRA 24.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>4 / 253 (1.58%)</p> <p>4</p> | <p>4 / 255 (1.57%)</p> <p>6</p> | <p>13 / 252 (5.16%)</p> <p>16</p> |
| <p>iron deficiency anaemia</p> <p>alternative dictionary used: MedDRA 24.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>0 / 253 (0.00%)</p> <p>0</p> | <p>4 / 255 (1.57%)</p> <p>4</p> | <p>0 / 252 (0.00%)</p> <p>0</p> |
| <p>lymphopenia</p> <p>alternative dictionary used: MedDRA 24.0</p> | | | |

| | | | |
|--|------------------------|------------------------|-----------------------|
| subjects affected / exposed occurrences (all) | 10 / 253 (3.95%) 13 | 11 / 255 (4.31%) 14 | 9 / 252 (3.57%) 10 |
| Gastrointestinal disorders | | | |
| abdominal discomfort | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 2 / 255 (0.78%) | 3 / 252 (1.19%) |
| occurrences (all) | 1 | 2 | 4 |
| diarrhoea | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 10 / 253 (3.95%) | 10 / 255 (3.92%) | 10 / 252 (3.97%) |
| occurrences (all) | 12 | 12 | 12 |
| gastritis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 4 / 255 (1.57%) | 2 / 252 (0.79%) |
| occurrences (all) | 1 | 4 | 2 |
| mouth ulceration | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 2 / 255 (0.78%) | 1 / 252 (0.40%) |
| occurrences (all) | 1 | 2 | 1 |
| nausea | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 5 / 253 (1.98%) | 11 / 255 (4.31%) | 12 / 252 (4.76%) |
| occurrences (all) | 5 | 13 | 14 |
| toothache | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 253 (0.40%) | 5 / 255 (1.96%) | 3 / 252 (1.19%) |
| occurrences (all) | 1 | 5 | 3 |
| Hepatobiliary disorders | | | |
| hepatic function abnormal | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 253 (0.00%) | 3 / 255 (1.18%) | 0 / 252 (0.00%) |
| occurrences (all) | 0 | 3 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| urticaria | | | |
| alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|--|------------------------|-------------------------|-------------------------|
| subjects affected / exposed occurrences (all) | 3 / 253 (1.19%) 3 | 3 / 255 (1.18%) 3 | 4 / 252 (1.59%) 4 |
| Endocrine disorders hypothyroidism alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) | 1 / 253 (0.40%) 1 | 1 / 255 (0.39%) 1 | 0 / 252 (0.00%) 0 |
| Infections and infestations covid-19 alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) | 9 / 253 (3.56%) 9 | 16 / 255 (6.27%) 16 | 13 / 252 (5.16%) 13 |
| gingivitis alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) | 1 / 253 (0.40%) 1 | 0 / 255 (0.00%) 0 | 1 / 252 (0.40%) 1 |
| herpes zoster alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) | 8 / 253 (3.16%) 8 | 9 / 255 (3.53%) 9 | 16 / 252 (6.35%) 18 |
| nasopharyngitis alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) | 17 / 253 (6.72%) 24 | 19 / 255 (7.45%) 21 | 18 / 252 (7.14%) 24 |
| upper respiratory tract infection alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) | 17 / 253 (6.72%) 19 | 21 / 255 (8.24%) 30 | 19 / 252 (7.54%) 27 |
| urinary tract infection alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) | 25 / 253 (9.88%) 38 | 32 / 255 (12.55%) 41 | 37 / 252 (14.68%) 47 |
| vulvitis alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|--|----------------------|----------------------|----------------------|
| subjects affected / exposed ^[10] occurrences (all) | 0 / 237 (0.00%) 0 | 0 / 238 (0.00%) 0 | 0 / 237 (0.00%) 0 |
| Metabolism and nutrition disorders hyperlipidaemia alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) | 1 / 253 (0.40%) 1 | 2 / 255 (0.78%) 2 | 6 / 252 (2.38%) 6 |
| hypertriglyceridaemia alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) | 4 / 253 (1.58%) 5 | 9 / 255 (3.53%) 9 | 3 / 252 (1.19%) 3 |
| hyperuricaemia alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) | 1 / 253 (0.40%) 2 | 2 / 255 (0.78%) 2 | 2 / 252 (0.79%) 2 |

| Non-serious adverse events | Placebo Maximum Extended Enrollment (MEE) | 2 mg Baricitinib (MEE) | 4 mg Baricitinib (MEE) |
|--|---|---------------------------|---------------------------|
| Total subjects affected by non-serious adverse events subjects affected / exposed | 17 / 21 (80.95%) | 14 / 20 (70.00%) | 17 / 20 (85.00%) |
| Vascular disorders hypertension alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) | 0 / 21 (0.00%) 0 | 1 / 20 (5.00%) 1 | 1 / 20 (5.00%) 1 |
| General disorders and administration site conditions chest discomfort alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) | 2 / 21 (9.52%) 4 | 0 / 20 (0.00%) 0 | 0 / 20 (0.00%) 0 |
| Reproductive system and breast disorders prostatitis alternative dictionary used: MedDRA 24.0 subjects affected / exposed ^[9] occurrences (all) | 0 / 1 (0.00%) 0 | 0 / 1 (0.00%) 0 | 0 / 20 (0.00%) 0 |
| Respiratory, thoracic and mediastinal | | | |

| | | | |
|--|--|--|---|
| disorders cough alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) | 2 / 21 (9.52%) 2 | 0 / 20 (0.00%) 0 | 1 / 20 (5.00%) 1 |
| Psychiatric disorders insomnia alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) | 1 / 21 (4.76%) 1 | 2 / 20 (10.00%) 2 | 0 / 20 (0.00%) 0 |
| Investigations alanine aminotransferase increased alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) blood creatine phosphokinase increased alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) hepatic enzyme increased alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) weight increased alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) | 1 / 21 (4.76%) 1 0 / 21 (0.00%) 0 2 / 21 (9.52%) 3 2 / 21 (9.52%) 4 | 0 / 20 (0.00%) 0 0 / 20 (0.00%) 0 0 / 20 (0.00%) 0 1 / 20 (5.00%) 1 | 2 / 20 (10.00%) 2 0 / 20 (0.00%) 0 1 / 20 (5.00%) 1 1 / 20 (5.00%) 1 |
| Nervous system disorders dizziness alternative dictionary used: MedDRA 24.0 subjects affected / exposed occurrences (all) headache alternative dictionary used: MedDRA 24.0 | 0 / 21 (0.00%) 0 | 1 / 20 (5.00%) 1 | 3 / 20 (15.00%) 4 |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 21 (4.76%) | 1 / 20 (5.00%) | 1 / 20 (5.00%) |
| occurrences (all) | 3 | 1 | 1 |
| hypoaesthesia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 0 / 21 (0.00%) | 2 / 20 (10.00%) | 0 / 20 (0.00%) |
| occurrences (all) | 0 | 4 | 0 |
| Blood and lymphatic system disorders | | | |
| anaemia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 3 / 21 (14.29%) | 2 / 20 (10.00%) | 2 / 20 (10.00%) |
| occurrences (all) | 4 | 2 | 2 |
| iron deficiency anaemia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 2 / 21 (9.52%) | 0 / 20 (0.00%) | 2 / 20 (10.00%) |
| occurrences (all) | 2 | 0 | 2 |
| lymphopenia | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 3 / 21 (14.29%) | 1 / 20 (5.00%) | 1 / 20 (5.00%) |
| occurrences (all) | 3 | 1 | 1 |
| Gastrointestinal disorders | | | |
| abdominal discomfort | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 21 (4.76%) | 2 / 20 (10.00%) | 0 / 20 (0.00%) |
| occurrences (all) | 1 | 4 | 0 |
| diarrhoea | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 1 / 21 (4.76%) | 2 / 20 (10.00%) | 1 / 20 (5.00%) |
| occurrences (all) | 1 | 2 | 1 |
| gastritis | | | |
| alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed | 2 / 21 (9.52%) | 0 / 20 (0.00%) | 0 / 20 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| mouth ulceration | | | |
| alternative dictionary used: MedDRA 24.0 | | | |

| | | | |
|---|--|--|--|
| <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>nausea</p> <p>alternative dictionary used: MedDRA 24.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>toothache</p> <p>alternative dictionary used: MedDRA 24.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>0 / 21 (0.00%)</p> <p>0</p> <p>0 / 21 (0.00%)</p> <p>0</p> <p>2 / 21 (9.52%)</p> <p>2</p> | <p>0 / 20 (0.00%)</p> <p>0</p> <p>1 / 20 (5.00%)</p> <p>1</p> <p>1 / 20 (5.00%)</p> <p>1</p> | <p>2 / 20 (10.00%)</p> <p>2</p> <p>2 / 20 (10.00%)</p> <p>2</p> <p>1 / 20 (5.00%)</p> <p>2</p> |
| <p>Hepatobiliary disorders</p> <p>hepatic function abnormal</p> <p>alternative dictionary used: MedDRA 24.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>0 / 21 (0.00%)</p> <p>0</p> | <p>2 / 20 (10.00%)</p> <p>2</p> | <p>1 / 20 (5.00%)</p> <p>2</p> |
| <p>Skin and subcutaneous tissue disorders</p> <p>urticaria</p> <p>alternative dictionary used: MedDRA 24.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>2 / 21 (9.52%)</p> <p>3</p> | <p>0 / 20 (0.00%)</p> <p>0</p> | <p>1 / 20 (5.00%)</p> <p>1</p> |
| <p>Endocrine disorders</p> <p>hypothyroidism</p> <p>alternative dictionary used: MedDRA 24.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> | <p>0 / 21 (0.00%)</p> <p>0</p> | <p>2 / 20 (10.00%)</p> <p>2</p> | <p>0 / 20 (0.00%)</p> <p>0</p> |
| <p>Infections and infestations</p> <p>covid-19</p> <p>alternative dictionary used: MedDRA 24.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>gingivitis</p> <p>alternative dictionary used: MedDRA 24.0</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>herpes zoster</p> <p>alternative dictionary used: MedDRA 24.0</p> | <p>0 / 21 (0.00%)</p> <p>0</p> <p>0 / 21 (0.00%)</p> <p>0</p> | <p>0 / 20 (0.00%)</p> <p>0</p> <p>2 / 20 (10.00%)</p> <p>4</p> | <p>0 / 20 (0.00%)</p> <p>0</p> <p>1 / 20 (5.00%)</p> <p>1</p> |

| | | | |
|--|-----------------------|-----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 21 (0.00%) 0 | 0 / 20 (0.00%) 0 | 1 / 20 (5.00%) 1 |
| nasopharyngitis alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed occurrences (all) | 0 / 21 (0.00%) 0 | 0 / 20 (0.00%) 0 | 1 / 20 (5.00%) 1 |
| upper respiratory tract infection alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed occurrences (all) | 5 / 21 (23.81%) 11 | 9 / 20 (45.00%) 17 | 7 / 20 (35.00%) 8 |
| urinary tract infection alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed occurrences (all) | 2 / 21 (9.52%) 2 | 3 / 20 (15.00%) 3 | 1 / 20 (5.00%) 1 |
| vulvitis alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed ^[10] occurrences (all) | 0 / 20 (0.00%) 0 | 1 / 19 (5.26%) 1 | 0 / 20 (0.00%) 0 |
| Metabolism and nutrition disorders | | | |
| hyperlipidaemia alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed occurrences (all) | 3 / 21 (14.29%) 4 | 4 / 20 (20.00%) 4 | 3 / 20 (15.00%) 3 |
| hypertriglyceridaemia alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed occurrences (all) | 5 / 21 (23.81%) 5 | 0 / 20 (0.00%) 0 | 1 / 20 (5.00%) 1 |
| hyperuricaemia alternative dictionary used: MedDRA 24.0 | | | |
| subjects affected / exposed occurrences (all) | 2 / 21 (9.52%) 3 | 3 / 20 (15.00%) 3 | 4 / 20 (20.00%) 4 |

Notes:

[9] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

[10] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.

Justification: Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|--|
| 07 December 2018 | <ul style="list-style-type: none">- Modified logistic regression analyses;- Clarified the definition of post-menopausal;- Data from types of chest imaging other than x-ray can be accepted for tuberculosis screening;- Arterial thromboembolic events (ATEs) adjudicated by a blinded clinical event committee;- Analysis Methods were revised;- Language was revised for missing data imputation;- Subgroup analysis has been removed from the protocol. |
| 20 April 2020 | <ul style="list-style-type: none">- Participant number and statistical analysis was revised to account for COVID-19 affected participants;- Protocol updated to include provisions put into place in order to assure the safety of trial participants and minimizing risks to trial integrity during the COVID-19 pandemic;- Schedule of activities was clarified;- Analysis of British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) endpoint was included in the protocol to supplement efficacy analyses;- Updated to clarify that while most concomitant medications should remain stable during the trial, reductions in dose for safety are permitted;- Updated to clarify that prohibited use of corticosteroids for SLE requires discontinuation from study drug, while use of prohibited doses of corticosteroids for other reasons may not require discontinuation of study drug;- An interim analysis has been added to assess the likelihood of trial failure time prior to trial conclusion in order to minimize participant exposure to an ineffective drug. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

One investigational site with seven participants was excluded from analysis due to confirmed misconduct.

Study terminated due to insufficient evidence to support a positive benefit: risk ratio.

Notes: